Opendata, web and dolomites

PMLingAML SIGNED

Using PML nuclear body biology to identify potential AML treatment targets

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PMLingAML project word cloud

Explore the words cloud of the PMLingAML project. It provides you a very rough idea of what is the project "PMLingAML" about.

decipher    functions    repair    leukemia    npm1c    incl    drug    dna    excision    underlying    rar    patient    flt3itd    nbs    vast    mouse    murine    scrutinised    status    combination    subset    function    pmlingaml    base    c65a    shown    treatment    previously    lethal    analysing    carry    myeloid    lsk    dactinomycin    models    cells    leukemogenesis    understanding    pml    strategies    mutation    pmlc62a    resolution    healthy    therapeutic    acute    stem    disrupted    formerly    bone    knock    cellular    imaging    cured    outcome    trial    successful    share    model    disruption    poor    samples    roles    nuclear    mechanisms    mutated    patients    relationship    assuredly    marrows    therapy    body    localisation    dynamics    aml    pathogenesis    ber    alpha    damage    promyelocytic    elucidating    mass    biology    spectrometry    respective    clinical    inter    initiation    apl    leukemic    majority    identification    sumoylome    npm1    progenitor    oncoprotein    promyelocytes    hematopoietic    mimics    isolated    nb   

Project "PMLingAML" data sheet

The following table provides information about the project.

Coordinator
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE 

Organization address
address: RUE DE TOLBIAC 101
city: PARIS
postcode: 75654
website: www.inserm.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 184˙707 €
 EC max contribution 184˙707 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2020
 Duration (year-month-day) from 2020-09-01   to  2022-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) coordinator 184˙707.00

Map

 Project objective

Understanding the initiation and development of acute myeloid leukemia (AML) represents an important challenge which may lead to the identification of new therapeutic strategies. Acute promyelocytic leukemia (APL) was formerly the most lethal subset of AML; however, today the vast majority of APL patients can be cured by combination therapy. Therefore, fully understanding the mechanisms underlying successful treatment, by analysing the biology of APL pathogenesis will assuredly improve the management of AML subsets associated with a poor outcome, such as NPM1-mutated AML. Using a novel knock-in mouse model, PmlC62A/C65A, which mimics Pml nuclear body (NB) disruption induced by the main oncoprotein PML-RARα in APL, we have previously shown that Pml NBs are essential in APL pathogenesis and treatment response. Our project “PMLingAML” aims to carry on elucidating the impact of Pml NB disruption in APL, and then to apply this knowledge in other AML subsets. To this end, a mass spectrometry analysis will be conducted on both hematopoietic stem and progenitor (LSK) cells and promyelocytes isolated from healthy and leukemic murine bone marrows, to decipher the consequences of Pml NB disruption on the SUMOylome. Next, since PML NBs and NPM1 share common cellular functions and characteristics, we will analyse the inter-relationship between them; their localisation and dynamics will be assessed according to their respective status (disruption, mutation, knock-out), for example by high resolution imaging, both in various healthy and leukemic mouse models (incl NPM1c and NPM1c/FLT3ITD), and in patient samples. Their respective roles in response to a drug under clinical trial, Dactinomycin, will also be scrutinised. Finally, as DNA damage repair is an important function disrupted during leukemogenesis, the roles of Pml NBs and Npm1 will be assessed together with their inter-relationship, with particular focus on the base excision repair (BER) pathway.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PMLINGAML" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PMLINGAML" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

5G-ACE (2019)

Beyond 5G: 3D Network Modelling for THz-based Ultra-Fast Small Cells

Read More  

MacMeninges (2019)

Control of Central Nervous Sytem inflammation by meningeal macrophages, and its impairment upon aging

Read More  

MemoryAggregates (2020)

Mechanism of Whi3 Aggregation and its Age-dependent Malfunction

Read More